Three candidate antibodies—anti‐EpCAM, anti‐ASGPR, and anti‐GPC‐3—were selected to target these specific surface markers, aiming to achieve the desired sensitivity and specificity for HCC CTC identification. This evidence concerns the gene GPC3 and hepatocellular carcinoma.